Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer

被引:57
作者
Buim, Marcilei E. C. [1 ,2 ]
Fanelli, Marcello F. [3 ]
Souza, Virgilio S. [3 ]
Romero, Juliana [1 ]
Abdallah, Emne A. [1 ]
Mello, Celso A. L. [3 ]
Alves, Vanessa [1 ]
Ocea, Luciana M. M. [1 ]
Mingues, Natalia B. [1 ]
Barbosa, Paula N. V. P. [4 ]
Tyng, Chiang J. [4 ]
Chojniak, Rubens [4 ]
Chinen, Ludmilla T. D. [1 ]
机构
[1] AC Camargo Canc Ctr, Int Reserch Ctr, Sao Paulo, Brazil
[2] Univ Nove Julho, Dept Hlth, Sao Paulo, Brazil
[3] AC Camargo Canc Ctr, Dept Clin Oncol, Sao Paulo, Brazil
[4] AC Camargo Canc Ctr, Dept Image, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
circulating tumor cell; colorectal cancer; KRAs mutation; CHEMOTHERAPY PLUS BEVACIZUMAB; K-RAS; 1ST-LINE CHEMOTHERAPY; PROGNOSTIC-FACTOR; BREAST-CANCER; HETEROGENEITY; SURVIVAL; PROGRESSION; CETUXIMAB; ONCOGENE;
D O I
10.1080/15384047.2015.1070991
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Quantification of Circulating Tumor Cells (CTCs) as a prognostic marker in metastatic colorectal cancer (mCRC) has already been validated and approved for routine use. However, more than quantification, qualification or characterization of CTCs is gaining importance, since the genetic characterization of CTCs may reflect, in a real time fashion, genetic profile of the disease. Objective: To characterize KRAS mutations (codon 12 and 13) in CTCs from patients with mCRC and to compare with matched primary tumor. Additionally, correlate these mutations with clinical and pathological features of patients. Methods: Blood samples were collected from 26 patients with mCRC from the AC Camargo Cancer Center (SAo Paulo-Brazil). CTCs were isolated by ISET technology (Isolation by Size of Epithelial Tumors; Rarecells Diagnostics, France) and mutations analyzes were performed by pyrosequencing (QIAGEN). Results:KRAS mutation was detected in 7 of the 21 cases (33%) of samples from CTCs. In matched primary tumors, 9 of the 24 cases (37.5%) were found KRAS mutated. We observed that 5 of the 9 samples with KRAS mutation in their primary tumor had also KRAS mutation in CTCs, meaning a concordance of 71% of matched cases (P = 0.017). KRAS mutation neither on primary tumor nor in CTCs was associated with clinical-pathological parameters analyzed. Conclusion: Faced with a polyclonal disease like colorectal cancer, which is often treated with alternating and successive lines of chemotherapy, real time genetic characterization of CTCs, in a fast and feasible fashion, can provide important information to clinical management of metastatic patients. Although our cohort was limited, it was possible to show a high grade of concordance between primary tumor and CTCs, which suggests that CTCs can be used as surrogate of primary tumors in clinical practice, when the knowledge of mutation profile is necessary and the primary tumor is not available.
引用
收藏
页码:1289 / 1295
页数:7
相关论文
共 35 条
[1]   Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].
Baldus, Stephan E. ;
Schaefer, Karl-L. ;
Engers, Rainer ;
Hartleb, Dinah ;
Stoecklein, Nikolas H. ;
Gabbert, Helmut E. .
CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799
[2]   Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer [J].
Cohen, S. J. ;
Punt, C. J. A. ;
Iannotti, N. ;
Saidman, B. H. ;
Sabbath, K. D. ;
Gabrail, N. Y. ;
Picus, J. ;
Morse, M. A. ;
Mitchell, E. ;
Miller, M. C. ;
Doyle, G. V. ;
Tissing, H. ;
Terstappen, L. W. M. M. ;
Meropol, N. J. .
ANNALS OF ONCOLOGY, 2009, 20 (07) :1223-1229
[3]   Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer [J].
Cohen, Steven J. ;
Punt, Cornelis J. A. ;
Iannotti, Nicholas ;
Saidman, Bruce H. ;
Sabbath, Kert D. ;
Gabrail, Nashat Y. ;
Picus, Joel ;
Morse, Michael ;
Mitchell, Edith ;
Miller, M. Craig ;
Doyle, Gerald V. ;
Tissing, Henk ;
Terstappen, Leon W. M. M. ;
Meropol, Neal J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3213-3221
[4]   Circulating Tumor DNA to Monitor Metastatic Breast Cancer [J].
Weiss, Lukas ;
Hufnagl, Clemens ;
Greil, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :93-93
[5]   Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients [J].
de Albuquerque, Andreia ;
Kubisch, Ilja ;
Stoelzel, Ulrich ;
Ernst, Dominikus ;
Boese-Landgraf, Joachim ;
Breier, Georg ;
Stamminger, Gudrun ;
Fersis, Nikos ;
Kaul, Sepp .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[6]   Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].
De Roock, Wendy ;
Claes, Bart ;
Bernasconi, David ;
De Schutter, Jef ;
Biesmans, Bart ;
Fountzilas, George ;
Kalogeras, Konstantine T. ;
Kotoula, Vassiliki ;
Papamichael, Demetris ;
Laurent-Puig, Pierre ;
Penault-Llorca, Frederique ;
Rougier, Philippe ;
Vincenzi, Bruno ;
Santini, Daniele ;
Tonini, Giuseppe ;
Cappuzzo, Federico ;
Frattini, Milo ;
Molinari, Francesca ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Martini, Miriam ;
Bardelli, Alberto ;
Siena, Salvatore ;
Sartore-Bianchi, Andrea ;
Tabernero, Josep ;
Macarulla, Teresa ;
Di Fiore, Frederic ;
Gangloff, Alice Oden ;
Ciardiello, Fortunato ;
Pfeiffer, Per ;
Qvortrup, Camilla ;
Hansen, Tine Plato ;
Van Cutsem, Eric ;
Piessevaux, Hubert ;
Lambrechts, Diether ;
Delorenzi, Mauro ;
Tejpar, Sabine .
LANCET ONCOLOGY, 2010, 11 (08) :753-762
[7]   The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].
Diaz, Luis A., Jr. ;
Williams, Richard T. ;
Wu, Jian ;
Kinde, Isaac ;
Hecht, J. Randolph ;
Berlin, Jordan ;
Allen, Benjamin ;
Bozic, Ivana ;
Reiter, Johannes G. ;
Nowak, Martin A. ;
Kinzler, Kenneth W. ;
Oliner, Kelly S. ;
Vogelstein, Bert .
NATURE, 2012, 486 (7404) :537-540
[8]   Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion [J].
Domingos Chinen, Ludmilla T. ;
Lopes Mello, Celso A. ;
Abdallah, Emne Ali ;
Ocea, Luciana M. M. ;
Buim, Marcilei E. ;
Breve, Natalia M. ;
Gasparini Junior, Jose Luiz ;
Fanelli, Marcello F. ;
Paterlini-Brechot, Patrizia .
ONCOTARGETS AND THERAPY, 2014, 7 :1609-1617
[9]   Cytokeratin-based CTC counting unrelated to clinical follow up [J].
Domingos Chinen, Ludmilla Thome ;
de Carvalho, Fernanda Machado ;
Malagoli Rocha, Bruna Maria ;
Aguiar, Caroline Motta ;
Abdallah, Emne Ali ;
Campanha, Daniel ;
Mingues, Natalia Breve ;
de Oliveira, Thiago Bueno ;
Maciel, Macello Sampaio ;
Cervantes, Gustavo Marchioro ;
Dettino, Aldo L. A. ;
Soares, Fernando Augusto ;
Paterlini-Brechot, Patrizia ;
Fanelli, Marcello Ferretti .
JOURNAL OF THORACIC DISEASE, 2013, 5 (05) :593-+
[10]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247